Details of the Drug Combination

General Information of Drug Combination (ID: DCSDUHM)

Drug Combination Name
Ketamine Ketamine
Indication
Disease Entry Status REF
Postoperative Pain Management Phase 1 [1]
Component Drugs Ketamine   DMT5HA4 Ketamine   DMT5HA4
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indication(s) of Ketamine
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [2]
Anxiety N.A. Approved [3]
Bipolar disorder 6A60 Approved [3]
Depression 6A70-6A7Z Approved [3]
Traumatic brain injury NA07.Z Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Chronic pain MG30 Investigative [3]
Ketamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [6]
------------------------------------------------------------------------------------
Ketamine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [7]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Ketamine Interacts with 27 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [8]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Increases Expression [5]
Zinc finger protein SNAI1 (SNAI1) OTDPYAMC SNAI1_HUMAN Increases Expression [5]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Expression [9]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [9]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [5]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [10]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [11]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [12]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [13]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [13]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Decreases Expression [5]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Increases Expression [5]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [13]
TGF-beta receptor type-1 (TGFBR1) OT40S1SJ TGFR1_HUMAN Increases Expression [5]
TGF-beta receptor type-2 (TGFBR2) OT3P7GZP TGFR2_HUMAN Increases Expression [5]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Decreases Expression [13]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [14]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Increases Expression [11]
Leptin receptor (LEPR) OT9H7G0C LEPR_HUMAN Decreases Expression [13]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [14]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [14]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Affects Localization [14]
Sodium/hydrogen exchanger 6 (SLC9A6) OT5N47TC SL9A6_HUMAN Decreases Expression [12]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Response To Substance [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DOT(s)
Indication(s) of Ketamine
Disease Entry ICD 11 Status REF
Anaesthesia 9A78.6 Approved [2]
Anxiety N.A. Approved [3]
Bipolar disorder 6A60 Approved [3]
Depression 6A70-6A7Z Approved [3]
Traumatic brain injury NA07.Z Approved [3]
Coronavirus Disease 2019 (COVID-19) 1D6Y Phase 2 [4]
Chronic pain MG30 Investigative [3]
Ketamine Interacts with 1 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
N-methyl-D-aspartate receptor (NMDAR) TT9IK2Z NOUNIPROTAC Antagonist [6]
------------------------------------------------------------------------------------
Ketamine Interacts with 3 DME Molecule(s)
DME Name DME ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) DE4LYSA CP3A4_HUMAN Metabolism [7]
Cytochrome P450 2C9 (CYP2C9) DE5IED8 CP2C9_HUMAN Metabolism [7]
Cytochrome P450 2B6 (CYP2B6) DEPKLMQ CP2B6_HUMAN Metabolism [7]
------------------------------------------------------------------------------------
Ketamine Interacts with 27 DOT Molecule(s)
DOT Name DOT ID UniProt ID Mode of Action REF
Cytochrome P450 3A4 (CYP3A4) OTQGYY83 CP3A4_HUMAN Decreases Expression [8]
Zinc finger protein SNAI2 (SNAI2) OT7Y8EJ2 SNAI2_HUMAN Increases Expression [5]
Zinc finger protein SNAI1 (SNAI1) OTDPYAMC SNAI1_HUMAN Increases Expression [5]
Renin (REN) OT52GZR2 RENI_HUMAN Increases Expression [9]
Angiotensinogen (AGT) OTBZLYR3 ANGT_HUMAN Decreases Expression [9]
Transforming growth factor beta-1 proprotein (TGFB1) OTV5XHVH TGFB1_HUMAN Increases Expression [5]
Interleukin-1 beta (IL1B) OT0DWXXB IL1B_HUMAN Increases Secretion [10]
Fibronectin (FN1) OTB5ZN4Q FINC_HUMAN Increases Expression [5]
Cellular tumor antigen p53 (TP53) OTIE1VH3 P53_HUMAN Increases Expression [11]
Amyloid-beta precursor protein (APP) OTKFD7R4 A4_HUMAN Increases Expression [12]
Apoptosis regulator Bcl-2 (BCL2) OT9DVHC0 BCL2_HUMAN Decreases Expression [13]
Endoplasmic reticulum chaperone BiP (HSPA5) OTFUIRAO BIP_HUMAN Increases Expression [13]
Cadherin-1 (CDH1) OTFJMXPM CADH1_HUMAN Decreases Expression [5]
Protein S100-A4 (S100A4) OTLRGFSQ S10A4_HUMAN Increases Expression [5]
DNA damage-inducible transcript 3 protein (DDIT3) OTI8YKKE DDIT3_HUMAN Increases Expression [13]
TGF-beta receptor type-1 (TGFBR1) OT40S1SJ TGFR1_HUMAN Increases Expression [5]
TGF-beta receptor type-2 (TGFBR2) OT3P7GZP TGFR2_HUMAN Increases Expression [5]
Leptin (LEP) OT5Q7ODW LEP_HUMAN Decreases Expression [13]
Caspase-3 (CASP3) OTIJRBE7 CASP3_HUMAN Increases Activity [14]
Proliferation marker protein Ki-67 (MKI67) OTA8N1QI KI67_HUMAN Increases Expression [11]
Leptin receptor (LEPR) OT9H7G0C LEPR_HUMAN Decreases Expression [13]
Caspase-9 (CASP9) OTD4RFFG CASP9_HUMAN Increases Activity [14]
Caspase-6 (CASP6) OTXLD3EC CASP6_HUMAN Increases Activity [14]
Actin, aortic smooth muscle (ACTA2) OTEDLG8E ACTA_HUMAN Increases Expression [5]
Apoptosis regulator BAX (BAX) OTAW0V4V BAX_HUMAN Affects Localization [14]
Sodium/hydrogen exchanger 6 (SLC9A6) OT5N47TC SL9A6_HUMAN Decreases Expression [12]
Apolipoprotein E (APOE) OTFOWL2H APOE_HUMAN Decreases Response To Substance [15]
------------------------------------------------------------------------------------
⏷ Show the Full List of 27 DOT(s)

References

1 ClinicalTrials.gov (NCT01070108) Escalating Ketamine Doses and Pre-emption
2 FDA Approved Drug Products from FDA Official Website. 2019. Application Number: (ANDA) 076092.
3 Ketamine FDA Label
4 ClinicalTrials.gov (NCT04365985) Study of Immunomodulation Using Naltrexone and Ketamine for COVID-19. U.S. National Institutes of Health.
5 Ketamine-induced bladder fibrosis involves epithelial-to-mesenchymal transition mediated by transforming growth factor-1. Am J Physiol Renal Physiol. 2017 Oct 1;313(4):F961-F972. doi: 10.1152/ajprenal.00686.2016. Epub 2017 Mar 22.
6 Ketamine modulates theta and gamma oscillations. J Cogn Neurosci. 2010 Jul;22(7):1452-64.
7 Contribution of CYP3A4, CYP2B6, and CYP2C9 isoforms to N-demethylation of ketamine in human liver microsomes. Drug Metab Dispos. 2002 Jul;30(7):853-8.
8 Cytoskeleton interruption in human hepatoma HepG2 cells induced by ketamine occurs possibly through suppression of calcium mobilization and mitochondrial function. Drug Metab Dispos. 2009 Jan;37(1):24-31.
9 Ketamine hypertension and the renin-angiotensin system. Clin Exp Hypertens A. 1983;5(6):875-83. doi: 10.3109/10641968309081814.
10 Cellular consequences triggered by ketamine on exposure to human glioblastoma epithelial (LN-229) cells. J Biochem Mol Toxicol. 2023 Dec;37(12):e23484. doi: 10.1002/jbt.23484. Epub 2023 Jul 29.
11 Ketamine cystitis as a mimic of carcinoma in situ. Histopathology. 2009 Dec;55(6):705-8. doi: 10.1111/j.1365-2559.2009.03437.x.
12 Ketamine promotes the amyloidogenic pathway by regulating endosomal pH. Toxicology. 2022 Apr 15;471:153163. doi: 10.1016/j.tox.2022.153163. Epub 2022 Apr 1.
13 Lipoxin A4 methyl ester attenuated ketamine-induced neurotoxicity in SH-SY5Y cells via regulating leptin pathway. Toxicol In Vitro. 2023 Jun;89:105581. doi: 10.1016/j.tiv.2023.105581. Epub 2023 Mar 11.
14 Apoptotic insults to human HepG2 cells induced by S-(+)-ketamine occurs through activation of a Bax-mitochondria-caspase protease pathway. Br J Anaesth. 2009 Jan;102(1):80-9. doi: 10.1093/bja/aen322. Epub 2008 Nov 9.
15 The apolipoprotein E epsilon 4 allele is associated with blunting of ketamine-induced psychosis in schizophrenia. A preliminary report. Neuropsychopharmacology. 1998 Nov;19(5):445-8. doi: 10.1016/S0893-133X(98)00031-1.